Last reviewed · How we verify
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE)
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (generic name: DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE) is a drug developed by LUPIN LTD. It is currently FDA-approved.
At a glance
| Generic name | DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE |
|---|---|
| Sponsor | LUPIN LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety (Phase 3)
- forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM (N/A)
- A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Contr (NA)
- A Randomized, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed- and Fasted State Bioequivalence of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Phase 1)
- A Randomized Study of the Effects of Dapagliflozin+Saxagliptin in Addition to Metformin Versus Single Addition Saxagliptin or Dapagliflozin on Glucose Metabolism in Patients With DM2 Poorly Controlled (Phase 2)
- Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes: a Multicenter Cohort Study (N/A)
- QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance (N/A)
- Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE CI brief — competitive landscape report
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE updates RSS · CI watch RSS
- LUPIN LTD portfolio CI
Frequently asked questions about DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE
What is DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE?
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE) is a pharmaceutical drug developed by LUPIN LTD.
Who makes DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE?
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is developed and marketed by LUPIN LTD (see full LUPIN LTD pipeline at /company/lupin-ltd).
What is the generic name of DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE?
DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE is the generic (nonproprietary) name of DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE.
What development phase is DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE in?
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE is FDA-approved (marketed).
Related
- Manufacturer: LUPIN LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing